Edition:
United States
Pictures | Thu Aug 14, 2014 | 8:31pm EDT

Making an Ebola vaccine

Laboratory technicians of the company Icon Genetics prepare proteins from tobacco plants (Nicotiana benthamiana) for weighing in a laboratory in Halle, Germany August 14, 2014. Icon Genetics GmbH, a German biopharma firm, is helping in the fight against the deadly virus Ebola, by creating antibodies needed for the experimental drug known as ZMapp. REUTERS/Axel Schmidt

Laboratory technicians of the company Icon Genetics prepare proteins from tobacco plants (Nicotiana benthamiana) for weighing in a laboratory in Halle, Germany August 14, 2014. Icon Genetics GmbH, a German biopharma firm, is helping in the fight...more

Laboratory technicians of the company Icon Genetics prepare proteins from tobacco plants (Nicotiana benthamiana) for weighing in a laboratory in Halle, Germany August 14, 2014. Icon Genetics GmbH, a German biopharma firm, is helping in the fight against the deadly virus Ebola, by creating antibodies needed for the experimental drug known as ZMapp. REUTERS/Axel Schmidt
Close
1 / 12
A laboratory technician at Icon Genetics prepares proteins from tobacco plants for weighing in a laboratory in Halle, August 14, 2014. Scientists at the company have created so-called vectors - DNA used to make plants create antibodies - which are put into bacteria and then transferred into tobacco plants, or nicotiana benthamiana. REUTERS/Axel Schmidt

A laboratory technician at Icon Genetics prepares proteins from tobacco plants for weighing in a laboratory in Halle, August 14, 2014. Scientists at the company have created so-called vectors - DNA used to make plants create antibodies - which are...more

A laboratory technician at Icon Genetics prepares proteins from tobacco plants for weighing in a laboratory in Halle, August 14, 2014. Scientists at the company have created so-called vectors - DNA used to make plants create antibodies - which are put into bacteria and then transferred into tobacco plants, or nicotiana benthamiana. REUTERS/Axel Schmidt
Close
2 / 12
A tobacco plant is pictured in a laboratory at Icon Genetic in Halle, August 14, 2014. During a week's incubation period in a greenhouse, the plants produce antibodies for the Ebola virus. These antibodies are then extracted from the plant and the waste plant material is discarded. The antibodies can then be used in the drug Zmapp. REUTERS/Axel Schmidt

A tobacco plant is pictured in a laboratory at Icon Genetic in Halle, August 14, 2014. During a week's incubation period in a greenhouse, the plants produce antibodies for the Ebola virus. These antibodies are then extracted from the plant and the...more

A tobacco plant is pictured in a laboratory at Icon Genetic in Halle, August 14, 2014. During a week's incubation period in a greenhouse, the plants produce antibodies for the Ebola virus. These antibodies are then extracted from the plant and the waste plant material is discarded. The antibodies can then be used in the drug Zmapp. REUTERS/Axel Schmidt
Close
3 / 12
Victor Klimyuk, COO of Icon Genetics inspects tobacco plants in a laboratory in Halle, August 14, 2014. Klimyuk says the process can be used for fighting many different viruses or illnesses and that it is practical because it can be scaled up easily. REUTERS/Axel Schmidt

Victor Klimyuk, COO of Icon Genetics inspects tobacco plants in a laboratory in Halle, August 14, 2014. Klimyuk says the process can be used for fighting many different viruses or illnesses and that it is practical because it can be scaled up easily....more

Victor Klimyuk, COO of Icon Genetics inspects tobacco plants in a laboratory in Halle, August 14, 2014. Klimyuk says the process can be used for fighting many different viruses or illnesses and that it is practical because it can be scaled up easily. REUTERS/Axel Schmidt
Close
4 / 12
Laboratory technicians at Icon Genetics prepare tobacco plants for drying in a laboratory in Halle, August 14, 2014. There are no licensed treatments or vaccines for Ebola, a contagious hemorrhagic disease, but several biotech companies and research teams have been working on potential drugs. REUTERS/Axel Schmidt

Laboratory technicians at Icon Genetics prepare tobacco plants for drying in a laboratory in Halle, August 14, 2014. There are no licensed treatments or vaccines for Ebola, a contagious hemorrhagic disease, but several biotech companies and research...more

Laboratory technicians at Icon Genetics prepare tobacco plants for drying in a laboratory in Halle, August 14, 2014. There are no licensed treatments or vaccines for Ebola, a contagious hemorrhagic disease, but several biotech companies and research teams have been working on potential drugs. REUTERS/Axel Schmidt
Close
5 / 12
Victor Klimyuk, COO of Icon Genetics, speaks during an interview in a laboratory in Halle, August 14, 2014. So far only 10-12 doses of ZMapp have been made. REUTERS/Axel Schmidt

Victor Klimyuk, COO of Icon Genetics, speaks during an interview in a laboratory in Halle, August 14, 2014. So far only 10-12 doses of ZMapp have been made. REUTERS/Axel Schmidt

Victor Klimyuk, COO of Icon Genetics, speaks during an interview in a laboratory in Halle, August 14, 2014. So far only 10-12 doses of ZMapp have been made. REUTERS/Axel Schmidt
Close
6 / 12
A sign is placed on a greenhouse with tobacco plants at Icon Genetic in Halle, August 14, 2014. The WHO's panel of medical ethicists said several experimental drugs had passed the laboratory and animal study phases of development and should be fast-tracked into clinical trials and made available for compassionate use. REUTERS/Axel Schmidt

A sign is placed on a greenhouse with tobacco plants at Icon Genetic in Halle, August 14, 2014. The WHO's panel of medical ethicists said several experimental drugs had passed the laboratory and animal study phases of development and should be...more

A sign is placed on a greenhouse with tobacco plants at Icon Genetic in Halle, August 14, 2014. The WHO's panel of medical ethicists said several experimental drugs had passed the laboratory and animal study phases of development and should be fast-tracked into clinical trials and made available for compassionate use. REUTERS/Axel Schmidt
Close
7 / 12
A tobacco plant is pictured in a laboratory at Icon Genetic in Halle, August 14, 2014. Icon Genetics COO Victor Klimyuk says: "Our part is that we provided our colleagues from Mapp Biopharmaceuticals [and] also from Kentucky Bioprocessing, which is involved in vaccine manufacturing, with our production platform that was developed here at the Icon Genetics site here in Germany, Halle." REUTERS/Axel Schmidt

A tobacco plant is pictured in a laboratory at Icon Genetic in Halle, August 14, 2014. Icon Genetics COO Victor Klimyuk says: "Our part is that we provided our colleagues from Mapp Biopharmaceuticals [and] also from Kentucky Bioprocessing, which is...more

A tobacco plant is pictured in a laboratory at Icon Genetic in Halle, August 14, 2014. Icon Genetics COO Victor Klimyuk says: "Our part is that we provided our colleagues from Mapp Biopharmaceuticals [and] also from Kentucky Bioprocessing, which is involved in vaccine manufacturing, with our production platform that was developed here at the Icon Genetics site here in Germany, Halle." REUTERS/Axel Schmidt
Close
8 / 12
A laboratory technician prepares proteins from tobacco plants for weighing in a laboratory in Halle, August 14, 2014. REUTERS/Axel Schmidt

A laboratory technician prepares proteins from tobacco plants for weighing in a laboratory in Halle, August 14, 2014. REUTERS/Axel Schmidt

A laboratory technician prepares proteins from tobacco plants for weighing in a laboratory in Halle, August 14, 2014. REUTERS/Axel Schmidt
Close
9 / 12
Victor Klimyuk, COO of Icon Genetics, speaks during an interview in a laboratory in Halle, August 14, 2014. Klimyuk said he and his colleagues were glad that their work was going towards helping fight the virus. "We are glad to do whatever we can do to support our colleagues to address this problem which is currently existing and I think that was very good decision of the WHO to allow this vaccine to be used even before it went through all necessary clinical trials because you have to balance a threat: what is more risk? To treat this illness or to let people die," he said. REUTERS/Axel Schmidt

Victor Klimyuk, COO of Icon Genetics, speaks during an interview in a laboratory in Halle, August 14, 2014. Klimyuk said he and his colleagues were glad that their work was going towards helping fight the virus. "We are glad to do whatever we can do...more

Victor Klimyuk, COO of Icon Genetics, speaks during an interview in a laboratory in Halle, August 14, 2014. Klimyuk said he and his colleagues were glad that their work was going towards helping fight the virus. "We are glad to do whatever we can do to support our colleagues to address this problem which is currently existing and I think that was very good decision of the WHO to allow this vaccine to be used even before it went through all necessary clinical trials because you have to balance a threat: what is more risk? To treat this illness or to let people die," he said. REUTERS/Axel Schmidt
Close
10 / 12
A sign at Icon Genetics is pictured in Halle, August 14, 2014. REUTERS/Axel Schmidt

A sign at Icon Genetics is pictured in Halle, August 14, 2014. REUTERS/Axel Schmidt

A sign at Icon Genetics is pictured in Halle, August 14, 2014. REUTERS/Axel Schmidt
Close
11 / 12
Victor Klimyuk, COO of Icon Genetics, inspects tobacco plants in a laboratory in Halle, August 14, 2014. REUTERS/Axel Schmidt

Victor Klimyuk, COO of Icon Genetics, inspects tobacco plants in a laboratory in Halle, August 14, 2014. REUTERS/Axel Schmidt

Victor Klimyuk, COO of Icon Genetics, inspects tobacco plants in a laboratory in Halle, August 14, 2014. REUTERS/Axel Schmidt
Close
12 / 12

Next Slideshows

On Mount Sinjar

Among the Yazidi on the arid mountain.

Aug 14 2014

Cuba celebrates Fidel's birthday

Cubans young and old mark Fidel Castro's 88th birthday.

Aug 14 2014

Russian convoy heads to Ukraine

A Russian convoy approaches eastern Ukraine.

Aug 13 2014

When lightning strikes

Dramatic images of electrical storms.

Aug 13 2014

MORE IN PICTURES

Today in Sports

Today in Sports

Our top sports photography of the day.

At the epicenter of Mexico's earthquake

At the epicenter of Mexico's earthquake

Picking up the pieces in San Juan Pilcaya and Axochiapan, two towns near the epicenter of last week's devastating earthquake in central Mexico.

St. Croix damage from above

St. Croix damage from above

Aerial photos of the destruction to St. Croix following Hurricane Maria.

Puerto Rico in the dark

Puerto Rico in the dark

Much of the island is still without electricity five days after Maria struck with ferocious winds and torrential rains.

Athletes protest racial injustice

Athletes protest racial injustice

Athletes stage on-field protests against police brutality and racial injustice, as President Donald Trump called for owners to fire those who refuse to stand during the anthem.

Rio de Janeiro's drug war

Rio de Janeiro's drug war

Hundreds of Brazilian soldiers pour into Rio de Janeiro's Rocinha slum in a bid to help quell drug-related violence.

Best of Invictus Games

Best of Invictus Games

Highlights from the Invictus Games in Toronto, where more than 550 injured and wounded servicemen and women from 17 allied nations take part in 12 adaptive sports.

Cleaning up in the Florida Keys

Cleaning up in the Florida Keys

Residents survey the damage after Hurricane Irma blasts the Florida Keys.

Meet Team USA

Meet Team USA

Portraits of the athletes who will represent the United States at the 2018 Winter Olympics in Pyeongchang, South Korea.

Trending Collections

Pictures

Podcast